Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.42
$0.05(1.14%)
U.S. Market opens in 15h 42m

Evolus, Inc. Fundamental Analysis

Evolus, Inc. (EOLS) shows moderate financial fundamentals with a PE ratio of -4.82, profit margin of -20.49%, and ROE of 4.83%. The company generates $0.3B in annual revenue with strong year-over-year growth of 31.76%.

Key Strengths

Cash Position15.53%
PEG Ratio-0.79
Current Ratio2.02

Areas of Concern

ROE4.83%
Operating Margin-13.71%
We analyze EOLS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 92.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
92.0/100

We analyze EOLS's fundamental strength across five key dimensions:

Efficiency Score

Weak

EOLS struggles to generate sufficient returns from assets.

ROA > 10%
-26.74%

Valuation Score

Excellent

EOLS trades at attractive valuation levels.

PE < 25
-4.82
PEG Ratio < 2
-0.79

Growth Score

Excellent

EOLS delivers strong and consistent growth momentum.

Revenue Growth > 5%
31.76%
EPS Growth > 10%
25.00%

Financial Health Score

Excellent

EOLS maintains a strong and stable balance sheet.

Debt/Equity < 1
-5.39
Current Ratio > 1
2.02

Profitability Score

Weak

EOLS struggles to sustain strong margins.

ROE > 15%
4.83%
Net Margin ≥ 15%
-20.49%
Positive Free Cash Flow
No

Key Financial Metrics

Is EOLS Expensive or Cheap?

P/E Ratio

EOLS trades at -4.82 times earnings. This suggests potential undervaluation.

-4.82

PEG Ratio

When adjusting for growth, EOLS's PEG of -0.79 indicates potential undervaluation.

-0.79

Price to Book

The market values Evolus, Inc. at -9.81 times its book value. This may indicate undervaluation.

-9.81

EV/EBITDA

Enterprise value stands at -5.84 times EBITDA. This is generally considered low.

-5.84

How Well Does EOLS Make Money?

Net Profit Margin

For every $100 in sales, Evolus, Inc. keeps $-20.49 as profit after all expenses.

-20.49%

Operating Margin

Core operations generate -13.71 in profit for every $100 in revenue, before interest and taxes.

-13.71%

ROE

Management delivers $4.83 in profit for every $100 of shareholder equity.

4.83%

ROA

Evolus, Inc. generates $-26.74 in profit for every $100 in assets, demonstrating efficient asset deployment.

-26.74%

Following the Money - Real Cash Generation

Operating Cash Flow

Evolus, Inc. generates limited operating cash flow of $-50.36M, signaling weaker underlying cash strength.

$-50.36M

Free Cash Flow

Evolus, Inc. generates weak or negative free cash flow of $-56.43M, restricting financial flexibility.

$-56.43M

FCF Per Share

Each share generates $-0.87 in free cash annually.

$-0.87

FCF Yield

EOLS converts -19.96% of its market value into free cash.

-19.96%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.82

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.79

vs 25 benchmark

P/B Ratio

Price to book value ratio

-9.81

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.99

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-5.39

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.02

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

4.83

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How EOLS Stacks Against Its Sector Peers

MetricEOLS ValueSector AveragePerformance
P/E Ratio-4.8229.43 Better (Cheaper)
ROE483.05%800.00% Weak
Net Margin-20.49%-20145.00% (disorted) Weak
Debt/Equity-5.390.30 Strong (Low Leverage)
Current Ratio2.024.64 Strong Liquidity
ROA-26.74%-17936.00% (disorted) Weak

EOLS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evolus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

247.15%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

74.50%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

91.22%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ